Joint replacements are the #1 expenditure of Medicare. The process of approving these medical devices is flawed according to the Institute of Medicine. It is time for patients' voices to be heard as stakeholders and for public support for increased medical device industry accountability and heightened protections for patients. Post-market registry. Product warranty. Patient/consumer stakeholder equity. Rescind industry pre-emptions/entitlements. All clinical trials must report all data.
Please share what you have learned!
Twitter: @JjrkCh
Monday, May 8, 2017
Monsanto toxic chemicals, FDA corruption, 1994 and 2017
Labels:
antibiotics,
cancer,
FDA,
Monsanto,
patient safety,
toxic chemicals
Dallas, TX, USA
Washington, DC, USA
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment